Logo der Universitätsmedizin Mainz
Center for Thrombosis and Hemostasis (CTH)
 

Juniorgroup "Experimental Research"

Markus Bosmann, MD
Leader Juniorgroup "Experimental Research"

Sepsis and acute lung injury (ALI, ARDS) are life-threatening diseases and frequently require treatment in critical care medicine. The annual incidence of sepsis and ALI is approximately 150,000 cases in Germany. Immunocompromised patients are under increased risk for the development of infections, which can progress to sepsis or/and ALI. Additional complications can arise from severe disturbances in the blood clotting system (e.g. disseminated intravascular coagulopathy) during sepsis and ALI.

Accumulating evidence suggests a key role of the innate immune responses during sepsis and ALI. The release of a plethora of inflammatory mediators is observed and accompanied by complex interactions of intracellular signaling cascades. The focus of our research projects is on the roles and regulation of several of these mediators including Interleukin-27. IL-27 is a heterodimeric cytokine displaying pro-inflammatory properties during the acute inflammatory response but IL-27 can also mediate anti-inflammatory effects in chronic states of inflammation. In our current projects we aim to investigate the role of IL-27 and other mediators as well as signaling proteins during experimental sepsis and ALI. In addition, the interactions of the acute inflammatory response with blood coagulation are studied on a molecular level. This includes research on both the plasmatic clotting cascades as well as cellular components of coagulation (platelets).

Our studies will contribute to a better understanding of the pathogenesis of the aforementioned diseases, thereby helping to identify new avenues for therapeutic interventions.

Research Interests

  • Molecular pathogenesis of sepsis and acute lung injury (ALI)
  • Interactions of acute inflammation and the coagulation system
  • Role of immunologic mediators (e.g. IL-27) during innate immune responses
  • Investigation of the immune-modulatory properties of adrenergic receptor agonists

Partners of Collaboration

  • Matthias Theobald, M.D. (Professor of Medicine, Director of the III. Department of Medicine, Division of Hematology, Oncology, Pulmonology, University Medical Center Mainz)
  • Peter A. Ward, M.D. (Godfrey D. Stobbe Professor, Department of Pathology, University of Michigan, Ann Arbor, USA)
  • Heiko Mühl, Ph.D. (Professor of Pharmacology and Toxicology, Center of Pharmacology, Johann Wolfgang Goethe-University, Frankfurt a.M., Germany)
  • Peter J. Murray, Ph.D. (Associate Member, St. Jude Faculty, Departments of Infectious Diseases and Immunology, St. Jude Children’s Research Hospital, Memphis, USA)
  • Professor James H. Morrissey, University of Illinois, Urbana, USA

Research Funding

  • CTH/BMBF (Federal Ministry of Education and Research, Modul A, JG)
  • DFG (German Research Foundation, BO 3482/3-1)
  • MAIFOR Program
  • B. Braun Foundation
  • Internal university research funding, Level I     
  • EU Marie Curie Career Integration Grant (CIG)                                   

The team of the Juniorgroup for Experimental Research you will find in building 708, 2nd floor.

Team - Juniorgroup Experimental Research

Bosmann, MD
Markus Bosmann, MD

Position: Juniorgroup leader at the CTH, Assistant Physician

Phone 06131/17-8277
markus.bosmann@unimedizin-mainz.de

Higer, cand. med.
Maximilian Higer, cand. med.

Position: Candidate of the Doctoral Candidate-Fellowship-Program

mhiger@students.uni-mainz.de

Lars Langhanki

Position: PhD student

Phone 06131/17-8281
lars.langhanki@unimedizin-mainz.de

Riehl
Dennis Riehl

Position: PhD student / Candidate of the Doctoral Candidate-Fellowship-Program

Phone 06131/17-8281
dennis.riehl@unimedizin-mainz.de

Röwe, M.Sc.
Julian Röwe, M.Sc.

Position: PhD student

Phone 06131/17-8281
julian.roewe@unimedizin-mainz.de

References

  • Bosmann M, Grailer J.J., Ruemmler R, Russkamp N.F., Zetoune F.S., Sarma J.V., Standiford T.J., Ward P.A. Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury. The FASEB Journal. 2013 Aug 27. [Epub ahead of print]

  • Bosmann M, Ward P. Modulation of inflammation by interleukin-27. Journal of Leukocyte Biology. 2013 July 31. Epub ahead of print - doi:10.1189/jlb.0213107

  • Ward P. A., Bosmann M. A historical perspective on sepsis. The American Journal of Pathology. 2012 Jul;181(1):2-7. Epub 2012 May 26.

  • Bosmann M., Ward P. A. The inflammatory response in sepsis. Trends Immunology. 2012 Oct 2;1471-4906(12)00162-7.[Epub ahead of print].

  • Bosmann M., Ward P. A. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis (Review). Adv Exp Med Biol. 2012;946:147-59.

  • Bosmann M, Meta F, Ruemmler R, Haggadone MD, Sarma JV, Zetoune FS, Ward PA. Regulation of IL-17 Family Members by Adrenal Hormones During Experimental Sepsis in Mice. American Journal of Pathology. 2013 Apr;182(4):1124-30. doi: 10.1016/j.ajpath.2013.01.005.

  • Bosmann M., Zhu K., Grailer J. J., Matthay M. A., Sarma J. V., Zetoune F. S., Ward P. A. Anti-inflammatory Effects of ß2 Adrenergic Receptor Agonists in Experimental Acute Lung Injury. FASEB Journal. 2012 May;26(5):2137-44. Epub 2012 Feb 7.

  • Bosmann M., Sarma J. V., Atefi G., Zetoune F. S., Ward P. A. Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis. FASEB Journal. 2012 Apr;26(4):1640-51. Epub 2011 Dec 27.

  • Bosmann M., Patel V. R., Russkamp N. F., Pache F., Zetoune F. S., Sarma J. V., Ward P. A. MyD88-dependent production of IL-17F is modulated by the anaphylatoxin C5a: Role of the Akt signaling pathway. FASEB Journal. Feb 7. 2011 Dec;25(12):4222-32. Epub 2011 Aug 22.

  • Bosmann M., Haggadone M. D., Hemmila M. R., Zetoune F. S., Sarma J. V., Ward P. A. Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages. Journal of Immunology. 2012 May 15;188(10):5086-93. Epub 2012 Apr 9.